Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:1.3.1.51 (HDR)
605 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The method for determination of the active pellets' position in the Selectron vaginal tube is shown. A special steel cap shielding with narrow window mounted above the Therados RFA-3 semiconductor detector was constructed. By scanning along the Selectron line vaginal tube in air and water, for an appropriate distance with mild dose gradient, the actual active pellets' positions can be determined. The resolution was higher during scanning in the air than in water. The minimum number of tries for checking the whole system depends on the total number of pellet sources in the main safe, and the number of active pellets used. Advantages of this method, compared to other conventional methods for determination of the Selectron-HDR source positions, are associated with high resolution and capability of repetition without movement of the tube during checking procedure.
...
PMID:Determination of active pellets' position in the selectron-HDR vaginal tube using a therados RFA-3 water phantom system. 791 75

The feasibility of using a diamond detector for the dosimetry of brachytherapy sources has been investigated. A high-activity 192Ir source was selected for this purpose. The dosimetric characteristics measured included the photon fluence anisotropy in air, transverse dose profiles in planes parallel to the plane containing the HDR source and isodose distributions. The 'in-air' anisotropy of the photon fluence relative to seed orientation was measured at 5 and 10 cm from the source centre and compared with TLD measurements. Transverse dose distributions in planes parallel to the plane containing the source long axis were measured in a water phantom and compared with calculations performed with a treatment planning system. Isodose distributions were also measured in several planes around the 192Ir source. Measurements on two sources indicate that the 'in-air' photon fluence anisotropy measured by the diamond detector and the TLDs is very similar. Dose profiles measured at several distances from the source are also found to be in good agreement with the calculated dose profiles and isodose distributions. Results of this feasibility study indicate that the diamond detector, with its excellent spatial resolution and nearly tissue equivalent and isotropic radiation response, is an appropriate detector for dose measurements around brachytherapy sources.
...
PMID:Application of a diamond detector to brachytherapy dosimetry. 972 91

Clinical modulation of radiosensitivity via combined fractionated high dose rate and continuous ultra-low dose rate irradiation (ULDR) holds promise for the radiosensitization of human malignant gliomas. We measured both the in vitro and in vivo responses of a human malignant glioma cell line to combined continuous ULDR and high dose rate treatments. For in vitro ULDR treatments, U251 human malignant glioma cells were cultured in media containing tritiated water to yield a continuous dose rate of 0.03 Gy/hr. After exposures of 24, 48, or 72 hr, cells were acutely (1.1 Gy/min) irradiated, replated, and scored for colony formation. In vivo, U251 flank xenografts in nude mice had 125-iodine (125-I) seed brachytherapy at a dose rate of 0.05 Gy/hr. For whole-body continuous ULDR (0.03 Gy/hr), a 137-Cs source was mounted a fixed distance above the cages of animals bearing xenografts. After 3 days' continuous exposure, xenografts were acutely irradiated (2 Gy x 8 vs. 5 Gy x 2 daily fractions), and the regrowth delay in tumors was measured. In vitro, exposure to ULDR (0.03 Gy/hr) alone caused only modest killing and reduced the surviving fraction by approximately 0.2 logs after 72 hr exposure. The highest (10 Gy) dose of acute irradiation alone reduced survival by 1 log. However, U251 cell killing increased to 2.5 logs after combined HDR and ULDR treatments. Linear-quadratic modeling showed comparatively greater increase in the beta than the alpha coefficients of the linear-quadratic model for cell killing. In vivo, the 125-I seed brachytherapy treatments delayed tumor growth but resulted in no regression. The HDR treatments (5 Gy x 2 or 2 Gy x 8 daily fractions) caused growth delays (in days) of 17+/-2 or 16+/-2 (P=NS) days, respectively. The combined seed and 5 Gy x 2 or 2 Gy x 8 daily fractions regimen resulted in striking prolongation of regrowth delay (52.3+/-8.7 vs. 59.5+/-7.7 days) (P < 0.001 vs. HDR treatments alone). External ULDR alone caused no regression and minimal growth delay. Combined continuous external ULDR and the 5 Gy x 2 vs. 2 Gy x 8 daily fraction regimens resulted in prolongation of growth delay (33+/-0.9 (P=0.01 vs. 5 Gy x 2 daily fractions alone) vs. 35+/-0.7 (P=0.049 vs. 2 Gy x 8 daily fractions alone). We conclude that continuous ULDR increases the effect of HDR treatments of experimental malignant glioma. This increased effect may prove clinically important in the treatment of human malignant brain tumors.
...
PMID:Protracted exposure radiosensitization of experimental human malignant glioma. 988 41

The dose rate at point P at 0.25 cm in water from the transverse bisector of a straight catheter with an active stepping source (Nucletron microSelectron HDR source) with a dwell length of 2 cm was calculated using Monte Carlo code MCNP 4.A. The source step sizes were 1 cm and 0.25 cm. The Monte Carlo (MC) results were used for comparison with the results calculated with the Nucletron brachytherapy planning system (BPS) formalism, first with BPS variants and then with its respective MC calculated radial dose function and anisotropy function. The dose differences at point P calculated using the BPS formalism and variants are +15.4% and +3.1% for the source step size of 1 cm and 0.25 cm respectively. This reduction in dose difference is caused by the increased importance of errors in the anisotropy function with the smaller step size, which counter the errors in the radial dose function. Using the MC calculated radial dose function and anisotropy function with the BPS formalism. 1% dose calculation accuracy can be achieved, even in the near field, with negligible extra demand on computation time.
...
PMID:Dose errors in the near field of an HDR brachytherapy stepping source. 1007 Jul 87

1. The outcome of a course of radiotherapy is very dependent on the dose per fraction. The smaller the dose per fraction, as a general rule, the better the sparing of the late reacting normal tissues. 2. Overall treatment time is important, especially for tumours with a rapid doubling time. In such a case, the ideal of small doses per fraction (to save late reacting tissues) as well as a short overall treatment time (to offset the effect of repopulating) can be achieved by small doses per fraction applied two to three times per day, including Saturdays or weekends. 3. The BED (biologically effective dose) is a simple to use formula indicating the effects of fractionation. The most important term in the formula is the alpha/beta ratio which is available from experimental work for many tumours and tissues and can be looked up. As a guide, an alpha/beta ratio of 10 for early (acute) reaction and for tumour effects, and an alpha/beta ratio of 2 for late effects plus normal tissue complications can be used. 4. The application of the BED demonstrates that for HDR intracavitary therapy for cervical carcinoma, the biologically relevant dose lateral to point M(A) falls very much more rapidly than the nominal dose. Line sources are shown by comparison with other published reports, not to be intrinsically inferior to tandem ring/tandem ovoid systems and may have advantages the more cumbersome systems do not have, and may have the large advantage of allowing multiple small fractions without anaesthesia. For the particular line source system under discussion, water in a 40 cm3 Foleys bulb is used as the protecting medium for the posterior bladder wall and the anterior rectum. This particular system allows fraction sizes far smaller than 9.1 Gy at point (M)A, e.g. 3 Gy, which bestows an even greater benefit in terms of the therapeutic ratio according to BED10 and BED2 calculations.
...
PMID:Radiation related prognostic factors in radiation oncology. 1072 10

An experiment was carried out to reevaluate the response of LiF TLD-100 rods (1 mmx1 mmx6 mm) at different depths in a water substituting phantom to provide an answer to a prevailing controversy about the over-response of LiF to the softened photon spectra of 192Ir HDR source at depths in phantom due to its photon energy dependence. Claims of some authors that LiF TLDs over-responds by 8.5% at 10 cm depth in phantom, necessitating depth-dependent correction factors even for an 192Ir source and of some others for no over-response were evaluated. The over-response of LiF TLD-100 rods, against a calibrated ion chamber having a photon energy-independent response within 2%, was found to be not exceeding 2.5% at a depth of 10 cm in the phantom as compared to a depth at 1 cm, for a precision of the order of +/- 1% (1sigma) in the TLD measurements. By using ISO equivalent photon beams, photon energy dependence of the dosimeters was evaluated and for LiF TLD-100 rods it was found to be in close agreement (within 3%) with the ratios of mass energy absorption coefficients of LiF and water in the range of effective photon energy from 26 keV to 1.25 MeV. Parameters that could contribute to the discrepancy in the reported values of experimental results have been discussed.
...
PMID:In-phantom response of LiF TLD-100 for dosimetry of 192Ir HDR source. 1084 6

The effect of patient inhomogeneities surrounding the oesophagus on the dosimetry planning of an upper thoracic oesophageal 192Ir HDR brachytherapy treatment is studied. The MCNPX Monte Carlo code is used for dosimetry in a patient-equivalent phantom geometry and results are compared in terms of isodose contours as well as dose volume histograms with corresponding calculations by a contemporary treatment planning system software featuring a full TG-43 dose calculation algorithm (PLATO BPS version 14.2.4). It is found that the presence of patient inhomogeneities does not alter the delivery of the planned dose distribution to the planning treatment volume. Regarding the organs at risk, the common practice of current treatment planning systems (TPSs) to consider the patient geometry as a homogeneous water medium leads to a dose overestimation of up to 13% to the spinal cord and an underestimation of up to 15% to the sternum bone. These findings which correspond to the dose region of about 5-10% of the prescribed dose could only be of significance when brachytherapy is used as a boost to external beam therapy. Additionally, an analytical dosimetry model, which is efficient in calculating dose in mathematical phantoms containing inhomogeneity shells of materials of radiobiological interest, is utilized for dosimetry in the patient-equivalent inhomogeneous phantom geometry. Analytical calculations in this work are in good agreement with corresponding Monte Carlo results within the bone inhomogeneities of spinal cord and sternum bone but, like treatment planning system calculations, the model fails to predict the dose distribution in the proximal lung surface as well as within the lungs just as the TPS does, due to its inherent limitation in treating lateral scatter and backscatter radiation.
...
PMID:The effect of patient inhomogeneities in oesophageal 192Ir HDR brachytherapy: a Monte Carlo and analytical dosimetry study. 1527 81

MammoSite is a high-dose rate brachytherapy procedure for partial breast irradiation, which uses a balloon filled with radiopaque iodine-based contrast solution and catheter for insertion of 192Ir high-dose-rate source. The radiopaque material helps visualizing the balloon contour, catheter, and source position within the balloon, which is essential for computerized tomography-based treatment planning and for daily QA using x-ray radiographs. Because of the high content of iodine in contrast media, increased absorption and attenuation of photons may take place within the balloon, which would affect the resultant dose rates outside the balloon. The impact of the concentration of the radiopaque solution on the physical dosimetry of this brachytherapy procedure is investigated in this study using MCNPX (version 2.4) Monte Carlo simulation. Calculations were based on a 30 cm diameter water sphere phantom. The source geometry was that of the Nucletron microSelectron HDR v2 192Ir source. Concentration of the iodine-based radiopaque solution was varied from 5% to 25% by volume, a range recommended by the balloon's manufacturer. Balloon diameters of 4, 5, and 6 cm were simulated. Dose rate per unit air-kerma strength was calculated in 1 mm scoring bin steps. The dose rate reduction at the typical prescription line of 1 cm away from the balloon surface ranged from - 0.8% for the smallest balloon diameter and contrast concentration to a maximum of - 5.7% for the largest balloon diameter and contrast concentration, relative to a water-filled balloon. Limiting the contrast concentration to 10% would insure less than 3% reduction in the prescription dose, regardless of balloon diameter.
...
PMID:Contrast effects on dosimetry of a partial breast irradiation system. 1530 49

A durable recommendation for brachytherapy treatment planning systems to account for the effect of tissue, applicator and shielding material heterogeneities exists. As different proposed approaches have not been integrated in clinical treatment planning routine yet, currently utilized systems disregard or, most commonly, do not fully account for the aforementioned effects. Therefore, it is of interest to evaluate the efficacy of current treatment planning in clinical applications susceptible to errors due to heterogeneities. In this work the effect of the internal structure as well as the shielding used with a commercially available cylindrical shielded applicator set (Nucletron part # 084.320) for vaginal and rectum treatments is studied using three-dimensional Monte Carlo simulation for a clinical treatment plan involving seven source dwell positions of the classic microSelectron HDR 192Ir source. Results are compared to calculations of a treatment planning system (Plato BPS v.14.2.7), which assumes homogeneous water medium and applies a constant, multiplicative transmission factor only at points lying in the shadow of the shield. It is found that the internal structure of the applicator (which includes stainless steel, air and plastic materials) with no shield loaded does not affect the dose distribution relative to homogeneous water. In the unshielded side of the applicator with a 90 degrees, 180 degrees, or 270 degrees tungsten alloy shield loaded, an overestimation of treatment planning system calculations relative to Monte Carlo results was observed which is both shield and position dependent. While significant (up to 15%) at increased distances, which are not of major clinical importance, this overestimation does not affect dose prescription distances by more than 3%. The inverse effect of approx. 3% dose increase at dose prescription distances is observed for stainless steel shields. Regarding the shielded side of the applicator, it is shown that the default treatment planning system transmission factors for tungsten alloy result in a consistent dose over-estimation thus constituting a safe approach given the nature of associated clinical applications. Stainless steel is shown to be an ineffective shielding material with transmission factors reaching up to 0.68 at increased distances irrespective of shield geometry.
...
PMID:A monte carlo dosimetry study of vaginal 192Ir brachytherapy applications with a shielded cylindrical applicator set. 1558 61

The H-type Leipzig applicators are accessories of the microSelectron-HDR system (Nucletron, Veenendaal, The Netherlands) for treatment of superficial malignancies. Recently, the dose rate distributions in liquid water for the whole set of applicators using both source models available for the microSelectron-HDR afterloaders have been obtained by means of the experimentally validated Monte Carlo (MC) code GEANT4. Also an output table (cGy/hU) at 3 mm depth on the applicator central axis was provided. The output verification of these applicators by the user, prior to their clinical use, present practical problems: small detectors such as thermoluminescent dosimeters or parallel-plate ionization chambers are not easily used for verification in a clinical environment as they require a rigid setup with the Leipzig applicator and a phantom. In contrast, well-type ionization chambers are readily available in radiotherapy departments. This study presents a technique based on the HDR1000Plus well chamber (Standar Imaging) measurements with a special insert, which allows the output verification of the H-type Leipzig applicators on a routine basis. This technique defines correspondence factors (CF) between the in water dose rate output of the Leipzig applicators (cGy/hU) obtained with MC and the reading on the well chamber with the special insert, normalized to the HDR calibration factor with the HDR insert and to the source strength. To commission the applicators (with the well chamber and the special insert used), the physicist should check if the CF value agrees with its tabulated values presented in this work. If the differences are within 5% the tabulated output values can be used in clinical dosimetry. This technique allows the output validation of the Leipzig applicators with a well chamber widely used for HDR Ir-192 source strength measurements. It can easily be adapted to other types of well chambers for HDR source output verification.
...
PMID:Technique for routine output verification of Leipzig applicators with a well chamber. 2255 65


1 2 3 4 5 Next >>

---